CRISPR Therapeutics AGCRSPNASDAQ
LOADING
|||
EPS Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
51.25%
↑ 110% above average
Average (39q)
-496.56%
Historical baseline
Range
High:762.91%
Low:-20100.00%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 51.25% |
| Q2 2025 | -51.90% |
| Q1 2025 | -259.09% |
| Q4 2024 | 56.44% |
| Q3 2024 | 32.21% |
| Q2 2024 | -4.20% |
| Q1 2024 | -227.68% |
| Q4 2023 | 179.43% |
| Q3 2023 | -43.88% |
| Q2 2023 | -46.27% |
| Q1 2023 | 52.48% |
| Q4 2022 | 37.05% |
| Q3 2022 | 6.67% |
| Q2 2022 | -3.45% |
| Q1 2022 | -26.09% |
| Q4 2021 | -10.18% |
| Q3 2021 | -116.68% |
| Q2 2021 | 762.91% |
| Q1 2021 | 1.31% |
| Q4 2020 | -15.91% |
| Q3 2020 | -1.54% |
| Q2 2020 | -13.04% |
| Q1 2020 | -316.98% |
| Q4 2019 | -78.97% |
| Q3 2019 | 349.50% |
| Q2 2019 | -8.60% |
| Q1 2019 | -1.09% |
| Q4 2018 | 14.02% |
| Q3 2018 | -30.49% |
| Q2 2018 | -32.26% |
| Q1 2018 | -20100.00% |
| Q4 2017 | 100.50% |
| Q3 2017 | -10.71% |
| Q2 2017 | -3.70% |
| Q1 2017 | -225.58% |
| Q4 2016 | 216.22% |
| Q3 2016 | 13.95% |
| Q2 2016 | -48.28% |
| Q1 2016 | 30.95% |
| Q4 2015 | -90.91% |